Topiramate reduces levodopa-induced dyskinesia in the MPTP-lesioned marmoset model of Parkinson's disease

被引：50

作者：

Silverdale, MA

Nicholson, SL

Crossman, AR

Brotchie, JM

机构：

[1] Hope Hosp, Dept Neurol, Salford M6 8HD, Lancs, England

[2] Univ Manchester, Sch Biol Sci, Manchester Movement Disorder Lab, Manchester, Lancs, England

[3] Motac Neurosci Ltd, Manchester, Lancs, England

[4] Toronto Western Hosp, Toronto Western Res Inst, Toronto, ON M5T 2S8, Canada

来源：

MOVEMENT DISORDERS | 2005年 / 20卷 / 04期

基金：

中国国家自然科学基金;

关键词：

topiramate; dyskinesia; MPTP; Parkinson's disease;

D O I：

10.1002/mds.20345

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

Overactive AMPA receptor-mediated transmission may be involved in the pathogenesis of levodopa-induced dyskinesia. The mechanism of action of the anticonvulsant drug topiramate involves attenuation of AMPA receptor-mediated transmission. In this study, the potential antidyskinetic action of topiramate was examined in the MPTP-lesioned marmoset model of Parkinson's disease and levodopa-induced dyskinesia. Topiramate significantly reduced levodopa-induced dyskinesia, Without affecting the antiparkinsonian action of levodopa. Topiramate represents an exciting potential novel therapeutic approach to levoclopa-induced dyskinesia in patients with Parkinson's disease. (c) 2004 Movement Disorder Society.

引用

页码：403 / 409

页数：7

共 38 条

[1]

Abou-Khalil B, 2000, EPILEPSIA, V41, pS72

[2] Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature [J].